Thr138
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr138  -  PA1 (human)

Site Information
ILPRRPPtPEAQsEE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 468190

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 )
Disease tissue studied:
breast cancer ( 2 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 ) , lymphoma ( 5 ) , Burkitt's lymphoma ( 5 ) , follicular lymphoma ( 5 ) , mantle cell lymphoma ( 5 ) , melanoma skin cancer ( 3 )
Relevant cell line - cell type - tissue:

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290
27362937   Curated Info

3

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

4

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

5

Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42
24667141   Curated Info

6

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

7

Mulhern D (2011) CST Curation Set: 12822; Year: 2011; Biosample/Treatment: cell line, HEK 293/ku-0063794; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS*/T*) Immunoaffinity Beads Cat#: 5760
Curated Info

8

Mulhern D (2011) CST Curation Set: 12824; Year: 2011; Biosample/Treatment: cell line, HEK 293/PP242; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS*/T*) Immunoaffinity Beads Cat#: 5760
Curated Info

9

Mulhern D (2011) CST Curation Set: 12825; Year: 2011; Biosample/Treatment: cell line, HEK 293/PP242; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS*/T*) Immunoaffinity Beads Cat#: 5760
Curated Info

10

Mulhern D (2011) CST Curation Set: 12826; Year: 2011; Biosample/Treatment: cell line, HEK 293/WYE-354; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS*/T*) Immunoaffinity Beads Cat#: 5760
Curated Info

11

Mulhern D (2011) CST Curation Set: 12827; Year: 2011; Biosample/Treatment: cell line, HEK 293/WYE-354; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS*/T*) Immunoaffinity Beads Cat#: 5760
Curated Info

12

Mulhern D (2011) CST Curation Set: 12828; Year: 2011; Biosample/Treatment: cell line, HEK 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS*/T*) Immunoaffinity Beads Cat#: 5760
Curated Info

13

Mulhern D (2011) CST Curation Set: 12829; Year: 2011; Biosample/Treatment: cell line, HEK 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS*/T*) Immunoaffinity Beads Cat#: 5760
Curated Info

14

Mulhern D (2011) CST Curation Set: 12830; Year: 2011; Biosample/Treatment: cell line, HEK 293/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS*/T*) Immunoaffinity Beads Cat#: 5760
Curated Info

15

Mulhern D (2011) CST Curation Set: 12831; Year: 2011; Biosample/Treatment: cell line, HEK 293/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS*/T*) Immunoaffinity Beads Cat#: 5760
Curated Info

16

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

17

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

18

Possemato A (2010) CST Curation Set: 10716; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

19

Possemato A (2010) CST Curation Set: 10291; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

20

Possemato A (2010) CST Curation Set: 10139; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

21

Possemato A (2010) CST Curation Set: 10135; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

22

Guo A (2010) CST Curation Set: 9972; Year: 2010; Biosample/Treatment: cell line, 293/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368
Curated Info

23

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

24

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

25

Possemato A (2009) CST Curation Set: 6922; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info